Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Dare Bioscience Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-3.2-3.6
EPS (diluted, $ a share)$-0.18$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+2005.6%
Source

10-Q filed with the SEC, NASDAQ: DARE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Dare Bioscience, Inc.: key numbers

Share price
$0.5842Close, Nov 16
Market cap
$11.5M
Shares outstanding
19.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dare Bioscience, Inc.

All →
4:09 PM ET 8-K
Financial Results

Dare Bioscience Financial Results

Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.

Term
Q3 2026
9:03 AM ET 8-K
Capital Raise

Dare Bioscience Capital Raise

Stockholders of Daré Bioscience approved the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The approval was obtained at a special meeting held on November 10, 2026, ensuring compliance with dilution limits for a previously initiated capital raise.

4:02 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Dare Bioscience Nasdaq/NYSE Compliance Notice

Daré Bioscience received a deficiency notice from Nasdaq on September 28, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has until March 29, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing, and the company may be eligible for an additional 180-day compliance period if necessary.

Counterparty
Nasdaq
Term
180 days
9:01 AM ET 8-K
Investor Presentation

Dare Bioscience Investor Presentation

Daré Bioscience, Inc. filed a corporate presentation dated October 1, 2026, as an exhibit to its 8-K. The company intends to use this presentation in meetings with securities market participants and has made it available on its investor relations website.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.